| 中文关键词: 乳腺癌 分子靶向治疗 单克隆抗体 |
| 英文关键词:breast cancer molecular targeted therapy monoclonal antibody |
| 基金项目:辽宁省百千万人才工程项目（NO.2014921024） |
|
| 摘要点击次数: 3146 |
| 全文下载次数: 958 |
| 中文摘要: |
| 摘 要：近年来，乳腺癌的分子靶向治疗取得了长足的发展。曲妥珠单抗联合化疗已成为Her-2阳性乳腺癌患者的标准一线治疗。全文从抗Her-2治疗药物，PI3K/AKT/mTOR通路中的抑制剂，抗血管生成治疗药物，针对BRCA1/2突变的PARP抑制剂，细胞周期蛋白依赖性激酶4和6（CDK4/6）抑制剂几个方面就当前乳腺癌分子靶向治疗现状作一综述。 |
| 英文摘要: |
| Abstract：In recent years，the molecular targeted therapy for breast cancer has gained substantial development. Trastuzumab combined with chemotherapy has become the first-line therapy for Her-2 positive breast cancer patients. In this review，agents that target Her-2，inhibitors of PI3K/AKT/mTOR pathway，antiangiogenesis drugs，PARP inhibitors in BRCA1/2 mutation-associated patients and inhibitors of cyclin-dependent kinase4/6 are introduced. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
